“…Overall, mavacamten was effective, with a number needed to treat of 2, 3, and 4 at 30 weeks, respectively, for the endpoints of LVOT gradient reduction ≤50 mm Hg, improvement in NYHA by ≥1 class, and improvement to NYHA class I. 21 While such proportion of responders may be seen to compare unfavorably with published SRT results, it must be emphasized that patients enrolled in EXPLORER‐HCM were not immediate candidates for SRT (operative referral being an exclusion criterion), and that about two‐thirds were in NYHA class 2, while only the remaining third were in class 3. In addition, the results of a prospective double‐blind placebo‐controlled, randomized trial cannot be compared with those from retrospective SRT studies, in view of inherent limitations of the latter.…”